Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc(IRWD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
3-STAR RATING
STRONG BUY
BUY for 3 days
PROFIT SINCE LAST BUY
-0.82% ▼
LAST CLOSE
$4.83
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IRWD

11/13/2026: IRWD (3-star) is a STRONG-BUY. BUY for 3 days. Simulated Profits (-0.82%). Updated daily EoD!

Ironwood Pharmaceuticals Inc is a specialized biotechnology company known for its leading gastrointestinal franchise anchored by LINZESS. The company's main business strength lies in its lucrative profit-sharing partnership with AbbVie, which generates reliable cash flows and strong operating margins. Its primary growth opportunity centers on advancing its rare disease pipeline, notably apraglutide, to offset future revenue loss from the expected LINZESS patent cliff. Key risks include heavy revenue concentration, clinical execution hurdles, and upcoming generic competition. The stock best suits growth-oriented investors willing to weather binary clinical catalysts while monitoring pipeline progress and debt reduction.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile the rare disease pipeline offers growth catalysts, overall top-line expansion depends heavily on the lifecycle maturity of LINZESS.
Momentum investorStrong fit while signal remains positivePositive earnings beats and upward guidance revisions can drive short-term upward momentum.
Value investorMixed fitThe stock trades at attractive earnings multiples relative to cash generation, but patent expiration risks warrant caution.
Dividend investorWeak fitThe company does not pay dividends, retaining all earnings for debt paydown and clinical development.
Low-risk investorWeak fitHigh binary clinical risks and single-product revenue concentration create notable equity volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock frequently reacts sharply to clinical trial updates, earnings reports, and patent litigation outcomes.
Valuation riskMediumCurrent valuations factor in stable cash generation from LINZESS but leave little room for pipeline execution errors.
Competition risk (generic and branded GI therapies)HighAnticipated generic competition for LINZESS poses a severe threat to future baseline revenues.
Business qualityMediumThe company maintains high operating margins and efficient partnerships, but lacks broad portfolio diversification.
Dividend incomeLow / noneIncome-focused investors receive no cash return from dividends.
Execution riskHighSuccessful clinical trial execution and regulatory filings for apraglutide are critical to replacing future lost revenues.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 799.61M USD
Price to earnings Ratio 5.37
1Y Target Price 6.17
Price to earnings Ratio 5.37
1Y Target Price 6.17
Volume (30-day avg) 2.2M shares
Beta 0.24
52 Weeks Range 2.95 - 5.78
Updated Date 11/15/2026
52 Weeks Range 2.95 - 5.78
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.9

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -48.74%
Avg. Invested days 22
Today’s Advisory Strong Buy
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IRWD receives a 4-star rating, supported by strong unit economics, solid company fundamentals, and solid quantitative characteristics. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
IRWD has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+2629.2%) and strong cash generation (FCF margin 42.9%) are partially offset by negative revenue growth (-15.7%), soft profitability (net margin 8.1%), modest insider ownership of 3.51%.

Financial Health Rating

★★★★★
IRWD's financial health is supported by solid profitability, including gross margin of 100.0% and operating margin of 40.1%. Overall financial-health metrics support a 4-star score.

Growth Momentum Score

★★★★★
Earnings growth is IRWD's strongest growth driver at +2629.2% FY2025 versus FY2024 (strong, 5 stars). By comparison, free-cash-flow growth (+22.8%, solid) is also solid, while revenue growth (-15.7%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 97.5% and approximately 82.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.51% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 10.75%
Armistice Capital, LLC 8.42%
Sarissa Capital Management LP 5.55%
State Street Corp 5.32%
Bank of America Corp 5.25%

Unit Economics (Per $1K Revenue)

★★★★★
IRWD generates approximately $1,000 of gross profit, $401 of operating income, and $429 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 65.70%

Quantitative Style Profile

★★★★★
IRWD has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
U.S. LINZESS Collaboration RevenueThis profit-sharing arrangement drives the vast majority of the company's incoming cash flow.
Royalties and International LicensingProvides a secondary stream of passive international revenue.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When Before Market
Estimate 0.3
Actual 0.36

Profitability

Profit Margin 37.38%
Operating Margin (TTM) 62.88%

Management Effectiveness

Return on Assets (TTM) 45.82%
Return on Equity (TTM) -574.72%

Valuation

Trailing PE 5.37
Forward PE 12.33
Enterprise Value 1.05B
Price to Sales(TTM) 2
Enterprise Value 1.05B
Price to Sales(TTM) 2
Enterprise Value to Revenue 2.62
Enterprise Value to EBITDA 4.04
Shares Outstanding 165.55M
Shares Floating 137.08M
Shares Outstanding 165.55M
Shares Floating 137.08M
Percent Insiders 3.51
Percent Institutions 97.48

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.